Clinical trial
Sep 2026
An Open-Label, Dose-Escalation Trial of Psilocybin-Assisted Therapy for Bipolar II Depression.
Objective: Individuals with bipolar II disorder (BD-II) and depression face limited treatment options and are often excluded from psilocybin therapy trials due to concerns about precipitating mania or psychosis. The objective of this study was to evaluate the safety, tolerability, and preliminary efficacy of psilocybin...
Amanda E. Downey, B. Szigeti, Ellen R. Bradley et al.
· Journal of Clinical Psychiat... · 0 citations